Please check your internet connection and try again.
# Isoxsuprine Hydrochloride
## Overview
Isoxsuprine hydrochloride is a peripheral vasodilator that acts directly on vascular smooth muscle.
## Primary Indications
* Management of peripheral arterial disease (PAD), including intermittent claudication.
* Treatment of cerebrovascular insufficiency.
## Adult Dosing
* **Intermittent Claudication/PAD:** 10 mg to 20 mg orally every 3 to 4 times daily.
* **Cerebrovascular Insufficiency:** 10 mg to 20 mg orally every 3 to 4 times daily.
* Dosing may be titrated based on patient response and tolerance.
## Pediatric Dosing
* There is **no established pediatric dosing** for isoxsuprine hydrochloride. Use in pediatric populations is generally not recommended.
## Dose Adjustments
* **Renal Impairment:** No specific dose adjustment guidelines are established. Use with caution and consider reduced dosage in severe renal impairment.
* **Hepatic Impairment:** No specific dose adjustment guidelines are established. Use with caution and consider reduced dosage in severe hepatic impairment.
## Contraindications
* Hypersensitivity to isoxsuprine hydrochloride.
* Use in patients with recent arterial embolism or a history of thrombosis.
* Not recommended in congenital heart disease or significant hypotension.
## Adverse Effects
* **Common:** Nausea, vomiting, gastric distress, dizziness, weakness, flushing, **hypotension** (especially with rapid IV administration, which is not recommended for this indication).
* **Less Common:** Rash, pruritus, nervousness, constipation, drowsiness.
## Key Drug Interactions
* **Antihypertensives:** Isoxsuprine may potentiate the hypotensive effects of antihypertensive medications. Monitor blood pressure closely.
* **Sympathomimetic agents:** May have additive effects, potentially increasing adverse cardiovascular effects.
## Monitoring
* Blood pressure and heart rate.
* Signs and symptoms of peripheral circulation improvement (e.g., increased walking distance, reduced pain).
* Signs of adverse effects.
## Clinical Pearls
* Oral administration is the standard route for PAD and cerebrovascular insufficiency.
* Therapeutic benefits may take several weeks to become apparent.
* Efficacy in PAD is controversial, and its use may be limited in some regions due to lack of robust evidence and availability of alternative therapies.
***
*Please verify current prescribing information and institutional protocols before administration. This information is intended for healthcare professionals.*
